Patents by Inventor Patton E. Garay

Patton E. Garay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Cancer Using Opioid Retargeted Endopepidases
    Publication number: 20110064713
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 17, 2011
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Botulinum toxin screening assays
    Patent number: 7645570
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: January 12, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
  • BOTULINUM TOXIN SCREENING ASSAYS
    Publication number: 20090317839
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 24, 2009
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
  • BOTULINUM TOXIN SCREENING ASSAYS
    Publication number: 20090263836
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.
    Type: Application
    Filed: May 20, 2009
    Publication date: October 22, 2009
    Applicant: ALLERGAN, INC.
    Inventors: ESTER FERNANDEZ-SALAS, Birgitte P.S. Jacky, Patton E. Garay, Kei Roger Aoki
  • Botulinum toxin screening assays
    Patent number: 7598027
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: October 6, 2009
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
  • BOTULINUM TOXIN SCREENING ASSAYS
    Publication number: 20080182799
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Application
    Filed: March 13, 2008
    Publication date: July 31, 2008
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki